Stereotypic progressions in psychotic behavior.
Dopamine receptor supersensitivity (DARSS) often is invoked as a mechanism possibly underlying disordered thought processes and agitation states in psychiatric disorders. This review is focused on identified means for producing DARSS and associating the role of other monoaminergic systems in modulating DARSS. Dopamine (DA) receptors, experimentally, are prone to become supersensitive and to thus elicit abnormal behaviors when coupled with DA or a receptor agonist. In intact (control) rats repeated DA D₁ agonist treatments fail to sensitize D₁ receptors, while repeated D₂ agonist treatments sensitize D₂ receptors. D₂ RSS is attenuated by a lesion with DSP-4 (N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine) in early postnatal ontogeny, indicating that noradrenergic nerves have a permissive effect on D₂ DARSS. However, if DSP-4 is co-administered with 5,7-dihydroxytryptamine to destroy serotonin (5-HT) nerves, then D₂ RSS is restored. In rats treated early in postnatal ontogeny with the neurotoxin 6-hydroxydopamine to largely destroy DA innervation of striatum, both repeated D₁ and D₂ agonists sensitize D₁ receptors. 5-HT nerves appear to have a permissive effect on D₁ DARSS, as a 5-HT lesion reduces the otherwise enhanced effect of a D₁ agonist. The series of findings demonstrate that DARSS is able to be produced by repeated agonist treatments, albeit under different circumstances. The involvement of other neuronal phenotypes as modulators of DARSS provides the potential for targeting a variety of sites in the aim to prevent or attenuate DARSS. This therapeutic potential broadens the realm of approaches toward treating psychiatric disorders.
Kostrzewa
Richard M
RM
Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, PO Box 70577, Johnson City, TN 37614, USA. kostrzew@etsu.edu
Kostrzewa
John P
JP
Kostrzewa
Rose Anna
RA
Kostrzewa
Florence P
FP
Brus
Ryszard
R
Nowak
Przemyslaw
P
D000818:Animals; D018450:Disease Progression; D018491:Dopamine Agonists / Q000378:metabolism; D006801:Humans; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology*; D011954:Receptors, Dopamine / Q000378:metabolism; D013239:Stereotyped Behavior / Q000502:physiology*
D018491:Dopamine Agonists; D011954:Receptors, Dopamine
Pharmacol Biochem Behav. 2000 Sep;67(1):11-5
11113478
J Neurochem. 1994 Oct;63(4):1282-90
7931280
Pharmacol Biochem Behav. 1993 Jul;45(3):737-40
8332633
Am J Drug Alcohol Abuse. 2009;35(3):161-77
19462300
J Pharmacol Exp Ther. 1997 Jan;280(1):268-76
8996206
Neurotox Res. 2003;5(1-2):111-8
12832226
Brain Res Dev Brain Res. 1993 Dec 17;76(2):233-8
8149589
Med J Aust. 2009 Feb 16;190(S4):S22-5
19220169
Neurotox Res. 2007 Jan;11(1):41-50
17449447
J Pharmacol Exp Ther. 1987 Jan;240(1):167-76
3100767
J Neurosci. 1989 Jan;9(1):125-33
2521511
Life Sci. 1991;48(26):PL129
1675416
Neurotox Res. 2004;6(4):317-25
15545015
Pharmacol Biochem Behav. 1993 Feb;44(2):487-9
8095344
Pharmacol Biochem Behav. 1995 Apr;50(4):649-53
7617714
Psychopharmacology (Berl). 1995 Jun;119(4):466-73
7480527
J Neurochem. 1998 Mar;70(3):889-98
9489707
Pharmacol Biochem Behav. 2004 May;78(1):47-56
15159133
Pharmacol Rep. 2009 Mar-Apr;61(2):311-8
19443944
Neurotox Res. 2007 Feb;11(2):131-44
17449455
Life Sci. 1983 Dec 19;33(25):2479-82
6227782
Pharmacol Biochem Behav. 1991 Jul;39(3):677-82
1686103
J Pharmacol Exp Ther. 1992 Jun;261(3):1000-7
1602367
J Pharmacol Exp Ther. 1985 Nov;235(2):287-95
3932640
Pharmacol Biochem Behav. 1992 Mar;41(3):621-3
1584843
Neurotox Res. 2004;6(6):457-62
15639779
Brain Res Dev Brain Res. 1993 Nov 19;76(1):59-65
8306431
Neurotox Res. 2008 Oct;14(2-3):121-8
19073420
Adv Exp Med Biol. 1988;235:159-67
2976249
Amino Acids. 2005 Mar;28(2):157-64
15750845
Pharmacol Biochem Behav. 1991 Jun;39(2):517-9
1682952
Pol J Pharmacol. 2001 Jul-Aug;53(4):319-29
11990078
J Pharmacol Exp Ther. 1985 Aug;234(2):447-55
3926987
Eur J Pharmacol. 1993 Aug 3;239(1-3):183-7
7901028
Neurotox Res. 2003;5(5):329-38
14715452
J Pharmacol Exp Ther. 1984 Nov;231(2):343-54
6149306
J Pharmacol Exp Ther. 1994 Jan;268(1):231-7
8301563
Neurosci Biobehav Rev. 1995 Spring;19(1):1-17
7770190
Brain Res Bull. 1994;34(2):161-7
7913871
Brain Res Dev Brain Res. 1993 Nov 19;76(1):87-93
8306435
Pharmacol Biochem Behav. 1991 Jan;38(1):215-8
1901995
Eur J Pharmacol. 1991 Dec 17;209(3):157-61
1686767
Synapse. 1987;1(2):133-52
2905529
Neurotox Res. 2008 Oct;14(2-3):79-96
19073416
Eur J Pharmacol. 1991 Oct 2;203(1):115-20
1839147
Pharmacol Biochem Behav. 2006 May;84(1):3-7
16675001